Global anticoagulant effects of a novel sulfated pentomanan oligosaccharide mixture

Basit Öğe Kaydı
dc.authoridMa, Qing/0000-0003-0123-9913
dc.authorwosidMa, Qing/A-8012-2008
dc.contributor.authorPiccolo, P
dc.contributor.authorIqbal, O
dc.contributor.authorDemir, M
dc.contributor.authorMa, Q
dc.contributor.authorGerbutavicius, R
dc.contributor.authorFareed, J
dc.date.accessioned2024-06-12T11:22:24Z
dc.date.available2024-06-12T11:22:24Z
dc.date.issued2001
dc.departmentTrakya Üniversitesien_US
dc.description.abstractPI-88 is a potent antiproliferative agent, which is developed for various indications in cancer. This agent is obtained from yeast fermentation and is primarily composed of pentamannose and tetramannose oligosaccharide units. PI-88 is capable of producing anticoagulant effects, which are mediated by heparin cofactor II. The purpose of this study was to determine the anticoagulant properties of PI-88 in native whole blood, freshly drawn from human volunteers, supplemented with PI-88 at various concentrations (0-100 mug/mL). Whole blood activated clotting time (ACT) was measured using Hemochron instruments. PI-88 produced a strong anticoagulant effect at 100 mug/mL (479.0 +/- 59.5 sec). This anticoagulant effect was comparable to that observed in interventional cardiology and open-heart surgery. At the lower level, PI-88 produced concentration-dependent effects on ACT. Using thromboelastographic techniques (TEG), the effect of PI-88 was measured in terms of various parameters. PI-88 produced potent anticoagulant effects in the TEG studies. At the concentration of 25 mug/mL, it produced a complete anticoagulant effect in whole blood. Whole blood samples supplemented with PI-88 showed a concentration-dependent decrease in the generation of various markers of clotting activation. These results clearly suggest that PI-88 exerts an anticoagulant effect in whole blood. Because of the low-molecular-weight nature and a novel mechanism of action, this new drug may be considered for further development, particularly in cancer patients.en_US
dc.identifier.doi10.1177/107602960100700212
dc.identifier.endpage152en_US
dc.identifier.issn1076-0296
dc.identifier.issue2en_US
dc.identifier.pmid11292193en_US
dc.identifier.scopus2-s2.0-0035078421en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage149en_US
dc.identifier.urihttps://doi.org/10.1177/107602960100700212
dc.identifier.urihttps://hdl.handle.net/20.500.14551/25894
dc.identifier.volume7en_US
dc.identifier.wosWOS:000167590100012en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.relation.ispartofClinical And Applied Thrombosis-Hemostasisen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subject[No Keywords]en_US
dc.titleGlobal anticoagulant effects of a novel sulfated pentomanan oligosaccharide mixtureen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu